Clinical trials: PTH
Hyperparathyroidism, Primary
18F-Fluorocholine for the Detection of Parathyroid Adenomas
The investigators are studying the ability of F18 labeled fluorocholine PET to localize parathyroid adenomas in patients with hyperparathyroidism prior to surgery.
- Trial name
- NCT03764007
- Testing
- 18F-Fluorocholine, Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Thomas Hope
Calcium Deficiency, Vitamin D Deficiency
Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants
The purpose of this study is to demonstrate that the intestinal absorption of calcium from a newly developed calcium carbonate-vitamin D3 chewable tablet formulation increases the amount of calcium excreted in urine and decreases…
- Trial name
- Osteopro (NCT01639222)
- Testing
- Calcium 500 mg and Vitamin D3 800 IU, Low calcium meals
- Where
- Germany
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Takeda
DiGeorge Anomaly, Complete DiGeorge Anomaly
Phase I/II Thymus Transplantation With Immunosuppression #950
The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously described as transplantation) with tailored immunosuppression based on the recipient's pre-implantation T cell population is a safe and…
- Conditions
- DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome
- Trial name
- #950 (NCT00579527)
- Testing
- Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Anorexia Nervosa, Osteoporosis
The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Decreased bone strength is a common and serious medical problem present in many women with anorexia nervosa, or disordered eating.
- Trial name
- NCT00759772
- Testing
- Teriparatide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts General Hospital
Osteoporosis, Bone Diseases, Endocrine
7 Day Continuous Parathyroid Hormone IV Infusion
Study consists of an eight day inpatient visit on the General Clinical Research Center. The investigators' specific aims are to: 1.
- Conditions
- Osteoporosis, Bone Diseases, Endocrine, Hyperparathyroidism
- Trial name
- NCT00377312
- Testing
- Parathyroid Hormone (1-34)
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Immune Deficiency Disorders, Severe Combined Immunodeficiency
Immune Disorder HSCT Protocol
This study hypothesizes that a reduced intensity immunosuppressive preparative regimen will establish engraftment of donor hematopoietic cells with acceptable early and delayed toxicity in patients with immune function disorders.
- Conditions
- Immune Deficiency Disorders, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, X-linked Agammaglobulinemia
- Trial name
- NCT01821781
- Testing
- Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Washington University School of Medicine
Hyperparathyroidism, Primary, Hypercalcemia
Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy
This study is designed to demonstrate the efficacy and to assess the safety of cinacalcet for the reduction of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy is indicated on the basis of an…
- Trial name
- NCT00975221
- Testing
- Cinacalcet
- Where
- 47 sites in United States, Australia and 5 more
- Volunteers
- 67 people
- Sponsor
- Amgen
Hypoparathyroidism, Endocrine System Diseases
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism
During the first four weeks of the trial, participants were randomly assigned to one of four groups: three groups received fixed doses of TransCon PTH and one group received placebo.
- Conditions
- Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Trial name
- PaTH Forward (NCT04009291)
- Testing
- TransCon PTH
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 59 people
- Sponsor
- Ascendis Pharma A/S
Secondary Hyperparathyroidism, Hemodialysis
Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD)
The purpose of this study is to evaluate the long-term safety of paricalcitol injection. Subjects will administer clinical supplies 3 times a week, 40 weeks at dialysis session in dose-titration manner, following 12 weeks of…
- Trial name
- NCT00701805
- Testing
- Paricalcitol
- Where
- 12 sites in Japan
- Volunteers
- 107 people
- Sponsor
- Abbott
Primary Hyperparathyroidism
Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
This study will evaluate whether blocking the mineralocorticoid receptor, alone, or in combination with the calcimimetic cinacalcet, can lower parathyroid hormone and calcium levels in primary hyperparathyroidism.
- Trial name
- NCT02525796
- Testing
- eplerenone, amiloride, Cinacalcet
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Brigham and Women's Hospital
Secondary Hyperparathyroidism
Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism
The purpose of this study is to evaluate the long term safety and efficacy of thrice weekly intravenous (IV) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in patients receiving…
- Trial name
- NCT01576146
- Testing
- Etelcalcetide
- Volunteers
- 30 people
- Sponsor
- KAI Pharmaceuticals